Clinical organ toxicity of antiarrhythmic compounds: Ocular and pulmonary manifestations

American Journal of Cardiology

Volumn 84, Issue 9 SUPPL. 1, 1999, Pages 37-45

  Pollak, P Timothy ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DEETHYLAMIODARONE; PROCAINAMIDE;

BRONCHOSPASM; COMORBIDITY; CONFERENCE PAPER; CORNEA DISEASE; COUGHING; DIABETES MELLITUS; DRUG BLOOD LEVEL; EYE TOXICITY; FEVER; HEART ARRHYTHMIA; HUMAN; ISCHEMIC HEART DISEASE; LIPIDOSIS; LUNG TOXICITY; LUPUS ERYTHEMATOSUS; MALAISE; OPTIC NERVE DISEASE; PRIORITY JOURNAL;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CORNEAL OPACITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG DISEASES; OPTIC NERVE DISEASES; RISK FACTORS;

EID: 0032747161     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00700-6     Document Type: Conference Paper

References (72)

1. Withering W. An account of the Foxglove and some of its medicinal uses with practical remarks on dropsy and other diseases. London: M. Swinney, 1785.
2. Sneader W. Drug Prototypes and Their Exploitation. 1995;John Wiley & Sons, New York.
3. Mautz F.R. Reduction of cardiac irritability by the epicardial and systemic administration of drugs as a protection in cardiac surgery. J Thorac Surg. 5:1936;612-628.
4. Mark L.C., Kayden J.J., Steele J.M., et al. The physiological disposition and cardiac effects of procaine-amide. J Pharmacol Exp Ther. 102:1951;5-15.
5. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo The Cardiac Arrhythmia Suppression Trial . N Engl J Med. 324:1991;781-788.
6. Jung F., DiMarco J.P. Antiarrhythmic drug therapy in the treatment of atrial fibrillation. Cardiol Clin. 14:1996;507-520.
7. Wright P. Untoward effects associated with practolol administration oculomucocutaneous syndrome . Br Med J. 1:1975;595-598.
8. Francois J. [Cornea verticillata]. Bull Soc Belge Ophthalmol. 150:1968;656-670.
9. Delage C., Lagace R., Huard J. Pseudocyanotic pigmentation of the skin induced by amiodarone a light and electron microscopic study . Can Med Assoc J. 112:1975;1205-1208.
10. D'Amico D.J., Kenyon K.R., Ruskin J.N. Amiodarone keratopathy drug-induced lipid storage disease . Arch Ophthalmol. 99:1981;257-261.
11. Nielsen C.E., Andreasen F., Bjerregaard P. Amiodarone induced cornea verticillata. Acta Ophthalmol (Copenh). 61:1983;474-480.
12. Orlando R.G., Dangel M.E., Schaal S.F. Clinical experience and grading of amiodarone keratopathy. Ophthalmology. 91:1984;1184-1187.
13. Pollak P.T., Sharma A.D., Carruthers S.G. Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. Am J Cardiol. 64:1989;1138-1143.
14. Thystrup J.D., Fledelius H.C. Retinal maculopathy possibly associated with amiodarone medication. Acta Ophthalmol (Copenh). 72:1994;639-641.
15. Feiner L.A., Younge B.R., Kazmier F.J., Stricker B.H., Fraunfelder F.T. Optic neuropathy and amiodarone therapy. Mayo Clin Proc. 62:1987;702-717.
16. Krieg P., Schipper I. [Bilateral optic neuropathy following amiodarone therapy]. Klin Monatsbl Augenheilkd. 200:1992;128-132.
17. Sundelin K., Norrsell K. Enlargement of extraocular muscles during treatment with amiodarone. Acta Ophthalmol Scand. 75:1997;333-334.
18. Borruat F.X., Regli F. Pseudotumor cerebri as a complication of amiodarone therapy. Am J Ophthalmol. 116:1993;776-777.
19. Flach A.J., Dolan B.J. Progression of amiodarone induced cataracts. Doc Ophthalmol. 83:1993;323-329.
20. Ingram D.V. Ocular effects in long-term amiodarone therapy. Am Heart J. 106:1983;902-905.
21. Mindel J.M. Amiodarone and optic neuropathy - a medicolegal issue. Surv Ophthalmol. 42:1998;358-359.
22. Mantyjarvi M., Tuppurainen K., Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol. 42:1998;360-366.
23. Cush J.J., Goldings E.A. Drug-induced lupus clinical spectrum and pathogenesis . Am J Med Sci. 290:1985;36-45.
24. Condemi J.J. SLE idiopathic or drug-induced? Geriatrics. 35:1980;81-88.
25. Rotmensch H.H., Liron M., Tupilski M., Laniado S. Possible association of pneumonitis with amiodarone therapy. Am Heart J. 100:1980;412-413.
26. Rakita L., Sobol S.M., Mostow N., Vrobel T. Amiodarone pulmonary toxicity. Am Heart J. 106:1983;906-915.
27. Finnegan M.J., Faragher E.B. Amiodarone and chronic lung fibrosis. Postgrad Med J. 61:1985;497-499.
28. Lee K.L., Tai Y.T. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias efficacy and safety . Clin Cardiol. 20:1997;372-377.
29. Singh S.N., Fisher S.G., Deedwania P.C., Rohatgi P., Singh B.N., Fletcher R.D. Pulmonary effect of amiodarone in patients with heart failure: The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF- STAT) Investigators. J Am Coll Cardiol. 30:1997;514-517.
30. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure meta-analysis of individual data from 6500 patients in randomised trials . Lancet. 350:1997;1417-1424.
31. Vorperian V.R., Havighurst T.C., Miller S., January C.T. Adverse effects of low dose amiodarone a meta-analysis . J Am Coll Cardiol. 30:1997;791-798.
32. Kennedy J.I. Jr. Clinical aspects of amiodarone pulmonary toxicity. Clin Chest Med. 11:1990;119-129.
33. Valle J.M., Alvarez D., Antunez J., Valdes L. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone a rare aetiology . Eur Resp J. 8:1995;470-471.
34. Conte S.C., Pagan V., Murer B. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone clinical, radiological and histological pattern . Monaldi Arch Chest Dis. 52:1997;24-26.
35. Jessurun G.A., Hoogenberg K., Crijns H.J. Bronchiolitis obliterans organizing pneumonia during low-dose amiodarone therapy. Clin Cardiol. 20:1997;300-302.
36. Oren S., Turkot S., Golzman B., London D., Ben-Dor D., Weiler Z. Amiodarone-induced bronchiolitis obliterans organizing pneumonia (BOOP). Respir Med. 90:1996;167-169.
37. Polkey M.I., Wilson P.O., Rees P.J. Amiodarone pneumonitis no safe dose . Respir Med. 89:1995;233-235.
38. Costa-Jussà F.R., Corrin B., Jacobs J.M. Amiodarone lung toxicity a human and experimental study . J Pathol. 143:1984;73-79.
39. Magro S.A., Lawrence E.C., Wheeler S.H., Krafchek J., Lin H.T., Wyndham C.R. Amiodarone pulmonary toxicity prospective evaluation of serial pulmonary function tests . J Am Coll Cardiol. 12:1988;781-788.
40. Somani P., Bandyopadhyay S., Gross S.A., Moraday F., Dicarlo L.A. Amiodarone and multilamellar inclusion bodies. Br J Clin Pharmacol. 24:1987;237-238.
41. Rotmensch H.H., Belhassen B., Swanson B.N., Shoshani D., Spielman S.R., Greenspon A.J., Greenspan A.M., Vlasses P.H., Horowitz L.N. Steady-state serum amiodarone concentrations relationships with antiarrhythmic efficacy and toxicity . Ann Intern Med. 101:1984;462-469.
42. Daniels J.M., Brien J.F., Massey T.E. Pulmonary fibrosis induced in the hamster by amiodarone and desethylamiodarone. Toxicol Appl Pharmacol. 100:1989;350-359.
43. Kudenchuk P., Pierson D., Greene H., Graham E., Sears G., Trobauch G. Prospective evaluation of amiodarone pulmonary toxicity. Chest. 86:1984;541-548.
44. Adams P.C., Holt D.W., Storey G.C., Morley A.R., Callaghan J., Campbell R.W. Amiodarone and its desethyl metabolite tissue distribution and morphologic changes during long-term therapy . Circulation. 72:1985;1064-1075.
45. Hostetler K.Y., Reasor M.J., Walker R.E., Yazaki P.J., Frazee B.W. Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats. Biochim Biophys Acta. 875:1986;400-405.
46. Camus P., Mehendale H.M. Pulmonary sequestration of amiodarone and desethylamiodarone. J Pharm Exp Ther. 237:1986;867-873.
47. Holt D.W., Tucker G.T., Jackson P.R., Storey G.C.A. Amiodarone pharmacokinetics. Am Heart J. 106:1983;840-847.
48. Pollak P.T., Sharma A.D., Carruthers S.G. Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am J Cardiol. 65:1990;1185-1191.
49. Martin W. Mechanisms of amiodarone pulmonary toxicity. Clin Chest Med. 11:1990;131-138.
50. Pollak P.T., Sami M. Acute necrotizing pneumonitis and hyperglycemia after amiodarone therapy case report and review of amiodarone-associated pulmonary disease . Am J Med. 76:1984;935-939.
51. Marchlinski F.E., Gansler T.S., Waxman H.L., Josephson M.E. Amiodarone pulmonary toxicity. Ann Intern Med. 97:1982;839-845.
52. Shepherd N.A., Dawson A.M., Crocker P.R., Levison D.A. Granular cells as a marker of early amiodarone hepatotoxicity a pathological and analytical study . J Clin Pathol. 40:1987;418-423.
53. Kannan R., Sharma J.S.M., Guha M., Venkataraman K. Desethylamiodarone-induced phospholipidosis in lung, liver, and pulmonary macrophages and its relationship to tissue drug accumulation in rats. (Abstr.) Eur J Pharmacol. 183:1990;2452-2453.
54. Heath M.F., Costa-Jussà F.R., Jacobs J.M., Jacobson W. The induction of pulmonary phospholipidosis and the inhibition of lysosomal phospholipases by amiodarone. Br J Exp Pathol. 66:1985;391-397.
55. Chatelain P., Brotelle R. Phospholipid composition of rat lung after amiodarone treatment. Res Commun Chem Pathol Pharamcol. 50:1985;407-418.
56. Freedman A.P., Spielman S.R., Greenspan A.M., Horowitz L.N. Pulmonary function surveillance in amiodarone therapy. Am Rev Respir Dis. 129:1984;A52.
57. Cantor J.O., Osman M., Cerreta J.M., Suarez R., Mandl I., Turino G.M. Amiodarone-induced pulmonary fibrosis in hamsters. Exp Lung Res. 6:1984;1-10.
58. Cooper J.A. Jr, White D.A., Matthay R.A. Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs . Am Rev Respir Dis. 133:1986;488-505.
59. Shear N.H., Spielberg S.P., Grant D.M., Tang B.K., Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 105:1986;179-184.
60. Minchin R.F., Ho P.C., Boyd M.R. Reductive metabolism of nitrofurantoin by rat lung and liver in vitro. Biochem Pharmacol. 35:1986;575-580.
61. Fantone J.C., Phan S.H. Oxygen metabolite detoxifying enzyme levels in bleomycin-induced fibrotic lungs. Free Radic Biol Med. 4:1988;399-402.
62. Venkatesan N., Punithavathi V., Chandrakasan G. Curcumin protects bleomycin-induced lung injury in rats. Life Sci. 61:1997;L51-L58.
63. Kimbrough R.D. Toxic effects of the herbicide paraquat. Chest. 65:1974;65S-67S.
64. Kennedy T.P., Gordon G.B., Paky A., McShane A., Adkinson N.F. Jr, Peters S.P., Friday K., Jackman W., Sciuto A.M., Gurtner G.H. Amiodarone causes acute oxidant lung injury in ventilated and perfused rabbit lungs. J Cardiovasc Pharmacol. 12:1988;23-36.
65. Snider G.L., Hayes J.A., Korthy A.L. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin pathology and stereology . Am Rev Resp Dis. 117:1978;1099-1108.
66. Donica S.K., Paulsen A.W., Simpson B.R., et al. Danger of amiodarone therapy and elevated inspired oxygen concentrations in mice. Am J Cardiol. 77:1996;109-110.
67. Futamura Y. Toxicity of amiodarone on mouse pulmonary endothelial cells cultured with or without alveolar macrophages. J Toxicol Sci. 21:1996;253-267.
68. Martin W.J., Kachel D.L., Standing J.E. Alpha-tocopherol prevents amiodarone-mediated increase in cytosolic calcium and toxicity in cultured human pulmonary endothelial cells. Am Rev Respir Dis. 137:1989;423A.
69. Li ASW, Chignell CF. Spectroscopic studies of cutaneous photosensitizing agents. IX. A spin trapping study of the photolysis of amiodarone and desethylamiodrone.
70. Leeder R.G., Rafeiro E., Brien J.F., Mandin C.C., Massey T.E. Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro. J Biochem Toxicol. 11:1996;147-160.
71. Card J.W., Lalonde B.R., Rafeiro E., et al. Amiodarone-induced disruption of hamster lung and liver mitochondrial function lack of association with thiobarbituric acid-reactive substance production . Toxicol Lett. 98:1998;41-50.
72. Jessurun G.A., Boersma W.G., Crijns H.J. Amiodarone-induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment. Drug Safety. 18:1998;339-344.